Prime Medicine’s investigational Prime Editor PM-577a cleared for clinical testing in New Zealand after Medsafe accepted the company’s clinical trial application. The therapy targets Wilson’s disease, a monogenic disorder where correcting disease-causing genetic variants is the core strategy.